Skip to content

Key Insights into the Molecular Diagnostic Laboratory Market in Europe

Europe’s molecular diagnostics (MDx) market is evolving faster than ever. While infectious disease testing remains the operational backbone, the momentum is shifting toward genomics — redefining how laboratories invest, modernise, and compete.In this exclusive Clearstate LabPro MDx 2025 report, we uncover how Europe’s leading laboratories are adapting their molecular portfolios, infrastructure, and partnerships to deliver the next generation of precision diagnostics.

Download
Key Insights into the Molecular Diagnostic Laboratory Market in Europe

Key Takeaways

Infectious disease remains the foundation

High-throughput automation continues to anchor Europe’s MDx capacity.

Genomics is driving new investment

Oncology and genetic testing are accelerating adoption of NGS platforms.

Outsourcing gaps persist

Complex panels like NIPT and tumor assays remain heavily reliant on reference labs.

Consolidation is reshaping competition

Large centralized networks are redefining vendor engagement and service models.

Success belongs to integrators

Growth now depends on enabling smarter, connected lab ecosystems, not just product delivery.

Key Insights into the Molecular Diagnostic Laboratory Market in Europe – Now Available

Download the latest insights into the Molecular Diagnostic Laboratory Market in Europe